{"name":"Les Laboratoires des Médicaments Stériles","slug":"les-laboratoires-des-m-dicaments-st-riles","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"optimized quadruple therapy","genericName":"optimized quadruple therapy","slug":"optimized-quadruple-therapy","indication":"Other","status":"marketed"},{"name":"Anti Xa dosage","genericName":"Anti Xa dosage","slug":"anti-xa-dosage","indication":"Other","status":"marketed"},{"name":"Dosage of PT-INR","genericName":"Dosage of PT-INR","slug":"dosage-of-pt-inr","indication":"Other","status":"marketed"},{"name":"Enoxaparin 4000 IU","genericName":"Enoxaparin 4000 IU","slug":"enoxaparin-4000-iu","indication":"Other","status":"marketed"},{"name":"Pidogrel","genericName":"Pidogrel","slug":"pidogrel","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"standard quadruple therapy","genericName":"standard quadruple therapy","slug":"standard-quadruple-therapy","indication":"Tuberculosis (drug-susceptible)","status":"marketed"},{"name":"ENOXA®","genericName":"ENOXA®","slug":"enoxa","indication":"Acute gonococcal cervicitis","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"switch NPH to glargin","genericName":"switch NPH to glargin","slug":"switch-nph-to-glargin","indication":"Type 1 diabetes mellitus","status":"marketed"}]}],"pipeline":[{"name":"optimized quadruple therapy","genericName":"optimized quadruple therapy","slug":"optimized-quadruple-therapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"standard quadruple therapy","genericName":"standard quadruple therapy","slug":"standard-quadruple-therapy","phase":"marketed","mechanism":"Standard quadruple therapy combines four antimicrobial agents to treat infections, typically used in tuberculosis or Helicobacter pylori eradication.","indications":["Tuberculosis (drug-susceptible)","Helicobacter pylori infection (refractory cases)"],"catalyst":""},{"name":"Anti Xa dosage","genericName":"Anti Xa dosage","slug":"anti-xa-dosage","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dosage of PT-INR","genericName":"Dosage of PT-INR","slug":"dosage-of-pt-inr","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ENOXA®","genericName":"ENOXA®","slug":"enoxa","phase":"marketed","mechanism":"Enoxa is a small molecule drug, but its exact mechanism of action is unknown.","indications":["Acute gonococcal cervicitis","Acute gonococcal urethritis","Gonorrhea","Gonorrhea of pharynx","Gonorrhea of rectum"],"catalyst":""},{"name":"Enoxaparin 4000 IU","genericName":"Enoxaparin 4000 IU","slug":"enoxaparin-4000-iu","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pidogrel","genericName":"Pidogrel","slug":"pidogrel","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"switch NPH to glargin","genericName":"switch NPH to glargin","slug":"switch-nph-to-glargin","phase":"marketed","mechanism":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues and suppressing hepatic glucose production.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":8,"phaseCounts":{"marketed":8},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}